Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 6:47 PM
Ignite Modification Date:
2025-12-24 @ 6:47 PM
NCT ID:
NCT03873857
Eligibility Criteria:
Inclusion Criteria:
* Has a confirmed diagnosis of relapsed or refractory CLL.
* Patient for whom the physician has decided to initiate CLL treatment with venetoclax (mono and combo therapy), or up to 4 weeks after venetoclax treatment initiation
* Patient voluntarily agrees to participate in this study and signs informed consent form
Exclusion Criteria:
* Has contraindications to venetoclax as listed on the approved local label in Russian Federation.
* Has Richter syndrome
* Participated in a clinical trial with an investigative drug for CLL within 30 days prior to treatment initiation
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT03873857
Study Brief:
Protocol Section:
NCT03873857